Market revenue in 2023 | USD 6.1 million |
Market revenue in 2030 | USD 14.7 million |
Growth rate | 13.4% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 59.02% in 2023. Horizon Databook has segmented the Thailand head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
In Thailand, constant developments in cancer screening have positively impacted the market. Moreover, the active involvement of the government in implementing awareness and screening programs is expected to impact market growth positively.
Additionally, the high prevalence of head and neck cancer in the country is driving the head and neck cancer therapeutics market. In August 2021, MSD (Thailand) Ltd. collaborated with Cigna Insurance Plc. to launch the “Together4More Possibility” campaign in Thailand. This campaign aimed to increase awareness about cancer therapy.
The increasing awareness is expected to drive market growth in the country. To reduce the incidence and mortality associated with cancer, the National Cancer Institute of Thailand (NCI), in collaboration with various organizations, formulated and advanced the National Cancer Control Program (NCCP).
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Thailand head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account